Identification of a novel marker associated with risk for delayed chemotherapy-induced vomiting.

about

Identification of a novel marker associated with risk for delayed chemotherapy-induced vomiting.

Item

http://www.wikidata.org/entity/Q44973290

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Identification of a novel mark ...... chemotherapy-induced vomiting.

@en

Identification of a novel mark ...... chemotherapy-induced vomiting.

@nl

type

Item

label

Identification of a novel mark ...... chemotherapy-induced vomiting.

@en

Identification of a novel mark ...... chemotherapy-induced vomiting.

@nl

prefLabel

Identification of a novel mark ...... chemotherapy-induced vomiting.

@en

Identification of a novel mark ...... chemotherapy-induced vomiting.

@nl

P1476

Identification of a novel mark ...... chemotherapy-induced vomiting.

@en

P2093

Gerald M Higa

http://www.w3.org/2001/XMLSchema#string

Gerry Hobbs

http://www.w3.org/2001/XMLSchema#string

Miklos L Auber

http://www.w3.org/2001/XMLSchema#string

P2860

A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer.

Pharmacokinetics of aprepitant and dexamethasone after administration of chemotherapeutic agents and effects of plasma substance P concentration on chemotherapy-induced nausea and vomiting in Japanese cancer patients.

Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy.

American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.

Serotonin mechanisms in chemotherapy-induced emesis in cancer patients.

The severity and pattern of emesis following different cytotoxic agents.

Physiology of chemotherapy-induced emesis and antiemetic therapy. Predictive models for evaluation of new compounds.

Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy.

Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone.

Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.

P2888

s00520-012-1402-2

P304

2803-2809

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00520-012-1402-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-02-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22350597

http://www.w3.org/2001/XMLSchema#string